88nkdc13j2
Joined: 24 Dec 2010
Posts: 29
Read: 0 topics
Warns: 0/5
Location: England
|
 Posted: Tue 12:48, 15 Mar 2011 Post subject: News and FDA Updates for Santarus (NASDAQSNTS), Wu |
|
|
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com
On 12/22/09,[link widoczny dla zalogowanych], Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, announced it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC? (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.
On 12/22/09,[link widoczny dla zalogowanych], WuXi PharmaTech (NYSE:WX),[link widoczny dla zalogowanych], a leading pharmaceutical,[link widoczny dla zalogowanych], biotechnology,[link widoczny dla zalogowanych], and medical-device research and development outsourcing company, with operations in China and the United States, announced it had been selected for the Deloitte Technology Fast 500 Asia Pacific 2009 List, the only company in China to receive this award for the past six years.
The post has been approved 0 times
|
|
